Skip to main content
SpringerLink
Log in

Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer

  • Original articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Summary

To study the local immunological effects of intravesical bacillus Calmette-Guérin (BCG) therapy in superficial bladder cancer patients, the production of interleukin-1 (IL-1), IL-2, IL-6, tumour necrosis factor α (TNFα), and interferon γ (IFNγ) was investigated in the urine. Urine specimens were collected during the six weekly BCG instillations, before instillation, and 2, 4, 6, 8, and 24 h thereafter. Results were standardized to urine creatinine. In general, the concentration of IL-1 increased markedly during the first three BCG instillations, reaching a plateau from instillations 3 to 6. IL-2 was not detected after the first BCG instillation, but from the second instillation onwards the mean IL-2 concentration increased rapidly. With respect to IL-6, patients had relatively high levels in the urine after the first BCG instillation. A relatively moderate increase of the IL-6 concentration was observed during the following weeks. Like IL-2, TNFα was only detected after repeated BCG instillations. Generally the highest TNF levels were found after BCG instillation 5. The presence of IFNγ could not be demonstrated. With respect to the occurrence of the cytokines during the first 24 h after the BCG instillation, TNF, IL-2, and IL-6 were detectable 2 h after the instillation. In contrast, IL-1 seemed to appear later, i.e. from 4 h onwards. TNF decreased most rapidly; it was nearly absent in 6-h samples. Generally IL-2 was not detectable in the 8-h samples, whereas IL-1 and IL-6 were present up to 8 h after instillation of BCG. The presence of TNF was found less frequently than the presence of IL-1, IL-2, and IL-6. Neutralization experiments indicated that most of the IL-1 present in the urine after BCG treatment was IL-1α. In conclusion, activation of BCG-specific T cells was indicated by the detection of IL-2. The presence of IL-1, IL-6, and TNFα might suggest activation of macrophages by intravesically administered BCG, although production by other cell types cannot be excluded. It is suggested that these cytokines, in combination with the leucocytes that are known to be recruited to the bladder in reaction to the BCG treatment, may play an important role in the antitumour activity of BCG against bladder cancer. For monitoring purposes, collection of urine might be performed during the first 6 h after BCG instillations 4–6. A correlation between the presence of cytokines in the urine and the clinical response has yet to be evaluated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Böhle A, Gerdes J, Ulmer AJ, Hofstetter AG, Flad HD (1990) Effects of local BCG therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall. J Urol 144: 53

    PubMed  Google Scholar 

  2. Böhle A, Nowc C, Ulmer AJ, Musehold J, Gerdes J, Hofstetter AG, Flad HD (1990) Detection of urinary TNF, IL 1, and IL 2 after local BCG immunotherapy for bladder carcinoma. Cytokine 2: 175

    PubMed  Google Scholar 

  3. Brakenhoff JPJ, De Groot ER, Evers RF, Pannekoek H, Aarden LA (1987) Molecular cloning and expression of hybridoma growth factor inE. coli. J Immunol 139: 4116

    PubMed  Google Scholar 

  4. Chen L, Mory Y, Zilberstein A, Revel M (1988) Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-β2. Proc Natl Acad Sci USA 85: 8037

    PubMed  Google Scholar 

  5. Coe JE, Fledman JD (1966) Extracutaneous delayed hypersensitivity, particularly in the guinea pig bladder. Immunology 10: 127

    PubMed  Google Scholar 

  6. De Boer EC, De Jong WH, Van Der Meijden APM, Steerenberg PA, Witjes JA, Vegt PDJ, Debruyne FMJ, Ruitenberg EJ (1991) Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer: a flow cytofluorometric analysis. Urol Res 1: 45

    Google Scholar 

  7. De Boer EC, De Jong WH, Van Der Meijden APM, Steerenberg PA, Witjes JA, Vegt PDJ, Debruyne FMJ, Ruitenberg EJ (1991) Presence of activated lymphocytes in the urine of superficial bladder cancer patients after intravesical immunotherapy with bacillus Calmette-Guérin (BCG). Cancer Immunol Immunother 33: 411

    PubMed  Google Scholar 

  8. De Jong WH, De Boer EC, Van Der Meijden APM, Vegt P, Steerenberg PA, Debruyne FMJ, Ruitenberg EJ (1990) Presence of interleukin-2 in urine after intravesical treatment of superficial bladder cancer patients with bacillus Calmette-Guérin. Cancer Immunol Immunother 31: 182

    PubMed  Google Scholar 

  9. De Jong WH, De Boer EC, Van Der Meijden APM, Steerenberg PA, Debruyne FMJ (1991) Intravesical BCG administration in the guinea pig: II. Immunohistochemical characterization of cellular infiltrate after one or two cycles of intravesical BCG. Virchows Arch [B]: 61: 159

    Google Scholar 

  10. Dinarello CA (1989) Interleukin-1 and its biologically related cytokines. Adv Immunol 44: 153

    PubMed  Google Scholar 

  11. El-Demiry MIM, Hargreave TB, Busuttil A, James K, Chisolm GD (1986) Immunohistochemical identification of lymphocyte subsets and macrophages in normal human urothelium using monoclonal antibodies. Br J Urol 58: 436

    PubMed  Google Scholar 

  12. El-Demiry MIM, Smith G, Ritchie AWS, James K, Cumming JA, Hargreave TB, Chisolm GD (1987) Local immune responses after intravesical BCG treatment of carcinoma in situ. Br J Urol 60: 543

    PubMed  Google Scholar 

  13. Endo Y, Matsushima K, Oppenheim JJ (1986) Mechanism of in vitro antitumor effects of interleukin 1 (IL 1). Immunobiology 172: 316

    PubMed  Google Scholar 

  14. Engelhardt R, Mackensen A, Galanos C, Andreesen R (1990) Biological response to intravenously administered endotoxin in patients with advanced cancer. J Biol Response Mod 9: 480

    PubMed  Google Scholar 

  15. Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KB, Kenney JS, Lee AT, Kuo GC, Allison AC, Lowry SF, Cerami A (1989) Antibodies to cachectin/tumor necrosis factor reduce interleukin 1β and interleukin 6 appearance during lethal bacteremia. J Exp Med 170: 1627

    PubMed  Google Scholar 

  16. Frost H, Murray JL, Chaudri HA, Van Damme J (1990) Interleukin-6 induction by a muramyltripeptide derivative in cancer patients. J Biol Response Mod 9: 160

    PubMed  Google Scholar 

  17. Gardiner RA, Seymour GJ, Lavin MF, Strutton GM, Gemmel E, Hazan G (1986) Immunohistochemical analysis of the human bladder. Br J Urol 58: 19

    PubMed  Google Scholar 

  18. Geczy CL (1984) The role of lymphokines in delayed-type hypersensitivity reactions. Springer Semin Immunopathol 7: 321

    PubMed  Google Scholar 

  19. Hanna MG Jr, Snodgrass MJ, Zbar B, Rapp HJ (1973) Histopathology of tumor regression after intralesional injection ofMycobacterium bovis: IV. Development of immunity to tumor cells and BCG. J Natl Canc Inst 51: 1897

    Google Scholar 

  20. Helle M, Boeije L, Aarden LA (1988) Functional discrimination between interleukin 6 and interleukin 1. Eur J Immunol 18: 1535

    PubMed  Google Scholar 

  21. Herberman RB (1989) Lymphokine-activated killer cell activity. Immunol Today 8: 178

    Google Scholar 

  22. Kimball ES, Pickeral SF, Oppenheim JJ, Rossio JL (1984) Interleukin 1 activity in normal human urine. J Immunol 133: 257

    Google Scholar 

  23. Kishimoto T (1989) The biology of interleukin-6. Blood 74: 1

    PubMed  Google Scholar 

  24. Kleinerman ES, Herberman RB (1984) Tumoricidal activity of human monocytes: evidence for cytolytic function distinct from that of NK cells. J Immunol 133: 4

    PubMed  Google Scholar 

  25. Morales A (1989) BCG in the treatment of bladder cancer: state of the art. Prog Clin Biol Res 310: 3

    PubMed  Google Scholar 

  26. Mullin JM, Snock KV (1990) Effect of tumor necrosis factor on epithelial tight junctions and transepithelial permeability. Cancer Res 50: 2172

    PubMed  Google Scholar 

  27. Prescott S, James K, Hargreave TB, Chisholm GD, Smyth JF (1990) Radioimmunoassay detection of interferon-gamma in urine after intravesical Evans BCG therapy. J Urol 144: 1248

    PubMed  Google Scholar 

  28. Ratliff TL, Haaff EO, Catalona WJ (1986) Detection of interleukin 2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG. Clin Immunol Immunopathol 40: 375

    PubMed  Google Scholar 

  29. Ratliff TL, Gillen D, Catalona WJ (1987) Requirement of a thymus-dependent immune response for BCG-mediated antitumor activity. J Urol 137: 155

    PubMed  Google Scholar 

  30. Ratliff TL, (1989) Mechanisms of action of intravesical BCG for bladder cancer. Prog Clin Biol Res 310: 107

    PubMed  Google Scholar 

  31. Ruggiero V, Latham K, Baglioni C (1987) Cytostatic and cytotoxic activity of tumor necrosis factor on human cancer cells. J Immunol 138: 2711

    PubMed  Google Scholar 

  32. Sancéau J, Falcoff R, Beranger F, Carter DB, Wietzerbin J (1990) Secretion of interleukin-6 (IL-6) by human monocytes stimulated by muramyl dipeptide and tumour necrosis factor alpha. Immunology 69: 52

    PubMed  Google Scholar 

  33. Schamhart DHJ, Kurth K (1990) Detection of urinary IL-6 during intravesical BCG therapy (abstract). J Urol 143: 321A

  34. Semenzato G (1990) Tumor necrosis factor: a cytokine with multiple biological activities. Br J Cancer 61: 354

    PubMed  Google Scholar 

  35. Stötter H, Wiebke EA, Tomita S, Belldegrun A, Topalian S, Rosenberg SA, Lotze MT (1989) Cytokines alter target cell susceptibility to lysis II. Evaluation of tumor infiltrating lymphocytes. J Immunol 142: 1767

    PubMed  Google Scholar 

  36. Torrence RJ, Kavoussi LR, Catalona WJ, Ratliff TL (1988) Prognostic factors in patients treated with intravesical bacillus Calmette-Guérin for superficial bladder cancer. J Urol 139: 941

    PubMed  Google Scholar 

  37. Trinchieri G, Perussia B (1988) Immune interferon: a pleiotropic lymphokine with multiple effects. Immunol Today 6: 131

    Google Scholar 

  38. Valone SE, Rich EA, Wallis RS, Ellner JJ (1988) Expression of tumor necrosis factor in vitro by human mononuclear phagocytes stimulated with wholeMycobacterium bovis BCG and mycobacterial antigens. Infect Immun 56: 3313

    PubMed  Google Scholar 

  39. Van Damme J, De Ley M, Van Snick J, Dinarello CA, Billiau A (1987) The role of interferon-β1 and the 26kDa protein (interferon-β2) as mediators of the antiviral effects of interleukin 1 and tumor necrosis factor. J Immunol 139: 1867

    PubMed  Google Scholar 

  40. Van Der Meijden APM, Debruyne FMJ, Steerenberg PA, De Jong WH (1989) Aspects of non-specific immunotherapy with BCG in superficial bladder cancer: an overview. Prog Clin Biol Res 310: 11

    PubMed  Google Scholar 

  41. Van Der Meijden APM, Debruyne FMJ, Steerenberg PA, De Jong WH (1989) BCG-RIVM versus BCG-Tice versus mitomycin-C in superficial bladder cancer: rationale and design of the trial of the southeast co-operative urological group, The Netherlands. Prog Clin Biol Res 310: 11

    PubMed  Google Scholar 

  42. Van Kessel KPM, Verhoef J (1990) A view to a kill: cytotoxic mechanisms of human polymorphonuclear leukocytes compared with monocytes and natural killer cells. Pathobiology 58: 249

    PubMed  Google Scholar 

  43. Van Kooten C, Rensink I, Pascual-Salcedo D, Van Oers R, Aarden LA (1991) Monokine production by human T cells. J Immunol 146: 2654

    PubMed  Google Scholar 

  44. Van Oers MHJ, Van Der Heijden AAPAM, Aarden LA (1988) Interleukin 6 (IL-6) in serum and urine of renal transplant recipients. Clin Exp Immunol 71: 314

    PubMed  Google Scholar 

  45. Wallis RS, Fujiwara H, Ellner JJ (1986) Direct stimulation of monocyte release of interleukin 1 by mycobacterial protein antigens. J Immunol 136: 193

    PubMed  Google Scholar 

  46. Watson J, Mochizuki D, Gillis S (1980) T-cell growth factors: interleukin 2. Immunol Today 1: 113

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory for Pathology, National Institute of Public Health and Environmental Protection (RIVM), P. O. Box 1, 3720 BA, Bilthoven, The Netherlands

    E. C. De Boer, W. H. De Jong, P. A. Steerenberg & E. Tetteroo

  2. Central Laboratory of the Netherlands Red Cross Blood Transfusion Service, Amsterdam, The Netherlands

    L. A. Aarden, E. R. De Groot & E. J. Ruitenberg

  3. Department of Urology, University Hospital Nijmegen, Nijmegen, The Netherlands

    A. P. M. Van der Meijden & F. M. J. Debruyne

  4. Department of Urology, Grootziekengasthuis, 's-Hertogenbosch, The Netherlands

    A. P. M. Van der Meijden

  5. Department of Urology, St. Elisabeth Hospital, Leiderdorp, The Netherlands

    P. D. J. Vegt

  6. Institute of Infectious Diseases and Immunology, Faculty of Veterinary Medicine, State University Utrecht, Utrecht, The Netherlands

    E. J. Ruitenberg

Authors
  1. E. C. De Boer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. H. De Jong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. A. Steerenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L. A. Aarden
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Tetteroo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. R. De Groot
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. A. P. M. Van der Meijden
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. P. D. J. Vegt
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. F. M. J. Debruyne
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. E. J. Ruitenberg
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

De Boer, E.C., De Jong, W.H., Steerenberg, P.A. et al. Induction of urinary interleukin-1 (IL-1), IL-2, IL-6, and tumour necrosis factor during intravesical immunotherapy with bacillus Calmette-Guérin in superficial bladder cancer. Cancer Immunol Immunother 34, 306–312 (1992). https://doi.org/10.1007/BF01741551

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01741551

Key words

Search

Navigation